FDA broadens healthcare economic information safe harbor

In an effort to clear a hurdle to outcomes- and other forms of value-based contracts, and to help payers prepare for new products, FDA Tuesday issued new guidance on healthcare economic information. The guidance creates a broad safe harbor for drug and device manufacturers to communicate truthful, non-misleading information to payers about data

Read the full 531 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE